Notch1 (Mus musculus) – Function and Biological Roles OpenAI o3-deep-research-2025-06-26 98 citations 2026-03-20T00:43:40.321730

Notch1 (Mus musculus) – Function and Biological Roles

Introduction and Key Concepts

Notch1 (Neurogenic locus notch homolog 1) is a single-pass transmembrane receptor in the mouse, encoded by the Notch1 gene (UniProt Q01705). It belongs to the highly conserved Notch family of receptors (Notch1–4 in mammals) that mediate cell–cell communication and cell fate decisions (www.nature.com) (www.nature.com). Notch1 was originally identified by homology to Drosophila Notch (a “neurogenic” gene controlling nervous system development) and shares the fundamental role of regulating how cells differentiate during development and homeostasis (www.nature.com). In essence, Notch1 functions as a ligand-activated signaling receptor: when activated by neighboring cells, it directly influences gene transcription in the nucleus, thereby altering cell behavior. This pathway is crucial for many developmental processes and continues to operate throughout the lifespan, with roles in maintaining adult tissue structure and responding to injury (www.nature.com). Consistent with its broad importance, Notch signaling (and Notch1 in particular) has been linked to numerous human diseases, including developmental disorders and cancers (www.nature.com).

Structure and Processing: The Notch1 protein is produced as a large precursor (~2530 amino acids) that undergoes proteolytic processing and contains several defined domains important for its function. The extracellular region of mouse Notch1 features 36 EGF-like repeats (epidermal growth factor–like domains) which facilitate ligand binding (pmc.ncbi.nlm.nih.gov). Within these repeats, a specific segment (around EGF repeats 11–12) is critical for recognizing Notch ligands (such as Delta-like and Jagged family proteins) (pmc.ncbi.nlm.nih.gov). Adjacent to the EGF repeats is the negative regulatory region (NRR), composed of three cysteine-rich LIN-12/Notch repeats (LNRs) and a heterodimerization (HD) domain (pmc.ncbi.nlm.nih.gov). In the Golgi apparatus, the nascent Notch1 precursor is cleaved at the HD domain by a furin-like convertase (this is called the S1 cleavage), separating the protein into an N-terminal extracellular subunit and a C-terminal transmembrane subunit that remain non-covalently associated (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This processing yields the mature heterodimeric Notch1 receptor that is transported to the cell surface (pmc.ncbi.nlm.nih.gov). The LNR–HD region keeps the receptor in an autoinhibited conformation, preventing signaling in the absence of ligand (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Notch1 is activated through direct cell–cell contact. When a Notch ligand (e.g. DLL1, DLL4, JAG1, or JAG2 on a neighboring cell) binds to the Notch1 extracellular domain, it induces a conformational change and “pulling” force that exposes the receptor’s cleavage site in the HD domain (pmc.ncbi.nlm.nih.gov). This leads to the second proteolytic cut (the S2 cleavage) by ADAM-family metalloproteases at the cell surface (pmc.ncbi.nlm.nih.gov). After this ligand-triggered S2 cleavage, the remaining membrane-tethered fragment of Notch1 – called NEXT (Notch extracellular truncation) – is rapidly cleaved within its transmembrane segment by the γ-secretase complex (S3 cleavage) (pmc.ncbi.nlm.nih.gov). The γ-secretase enzyme (a multi-subunit protease complex including Presenilin) releases the Notch1 intracellular domain (NICD) from the membrane (pmc.ncbi.nlm.nih.gov). This NICD is the key effector of Notch signaling: it translocates from the cytoplasm into the nucleus to regulate gene expression (pmc.ncbi.nlm.nih.gov). The NICD contains several functional domains: an RBPJ association module (RAM) near its N-terminus, seven ankyrin repeats (ANK) that serve as protein–protein interaction surfaces, two nuclear localization sequences (NLS) flanking the ANK region (ensuring NICD enters the nucleus), and a C-terminal PEST domain rich in proline, glutamic acid, serine, threonine (pmc.ncbi.nlm.nih.gov). The PEST motif carries degradation signals that target NICD for ubiquitin-mediated proteasomal turnover, thereby limiting the duration of Notch1 signaling (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Notch1’s overall architecture is shared by other Notch receptors, with Notch2–4 having similar domain organization and differing mostly in the number of EGF repeats and length of their PEST regions (pmc.ncbi.nlm.nih.gov).

Activation Mechanism and Signaling Pathway

Once liberated by γ-secretase, the Notch1 intracellular domain (NICD) acts as a transcriptional regulator. Canonical Notch signaling involves NICD partnering with a DNA-binding protein of the CSL family (also known as RBPJ in mammals, CBF1/Su(H)/Lag-1 in other species) (www.nature.com) (pmc.ncbi.nlm.nih.gov). In the absence of NICD, RBPJ/CSL is bound to target gene promoters along with corepressor proteins and histone deacetylases, keeping those target genes silenced (pmc.ncbi.nlm.nih.gov). When NICD enters the nucleus, it directly binds to RBPJ/CSL, via the RAM and ankyrin domains, and converts it into a transcriptional activator complex (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). NICD binding displaces the pre-bound corepressors and allows recruitment of coactivator proteins – most importantly, a Mastermind-like (MAML) protein, which bridges NICD and CSL and helps recruit the transcriptional machinery (pmc.ncbi.nlm.nih.gov). The assembled NICD–CSL–MAML complex drives expression of Notch target genes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). A classic family of direct Notch targets are the Hairy/Enhancer of Split (HES) genes and their relatives the HEY genes, which encode transcriptional repressors that in turn modulate cell differentiation programs (pmc.ncbi.nlm.nih.gov). Thus, the primary outcome of Notch1 activation is changes in gene expression in the signal-receiving cell, typically leading to context-dependent effects like cell fate specification or inhibition of differentiation. Notch signaling is unusual in that the receptor itself (NICD fragment) becomes a part of the nuclear transcription factor complex, a mechanism often described as “signal transduction by proteolysis.” This directness bypasses second messengers and allows immediate transcriptional response to cell–cell interactions (www.nature.com). Importantly, Notch signaling is highly context-dependent – the same signal can have different outcomes depending on the cell type and the network of other signals and transcription factors present (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

The Notch pathway is conserved across metazoans and generally operates at short range, requiring cells to be in direct contact (pmc.ncbi.nlm.nih.gov). Mammals have five canonical Notch ligands (Delta-like 1, 3, 4 and Jagged-1, 2), which are themselves transmembrane proteins presented on adjacent cells (pmc.ncbi.nlm.nih.gov). Notch1–ligand binding is a unidirectional signaling event: the cell expressing the ligand acts as the “signaling” cell, and the cell expressing Notch1 receives the signal. Notch1 activation typically influences binary cell fate decisions – for example, helping one cell adopt a primary fate while its neighbors adopt an alternative fate, a process famously described as lateral inhibition in neurogenesis (pmc.ncbi.nlm.nih.gov). Notch1 can also mediate inductive signaling, where a steady Notch signal drives neighboring cells into a particular differentiated state. The specificity of action is partly achieved by the fact that Notch1’s influence is limited to the nucleus of the cell that produces NICD (there is no diffusion of NICD to other cells), and by the localized nature of ligand–receptor contact (often within epithelial cell junctions or niche microenvironments). After NICD initiates target gene transcription, its activity is attenuated by phosphorylation and ubiquitylation (primarily via the E3 ubiquitin ligase FBXW7 acting on the PEST domain), causing NICD degradation (pmc.ncbi.nlm.nih.gov). This built-in negative feedback ensures Notch1 signals are transient unless continually stimulated by ligand. Notch1 signaling can also be modulated by glycosylation of its EGF repeats (mediated by enzymes like Fringe), which alters ligand binding affinity and receptor activation (pmc.ncbi.nlm.nih.gov).

Recent insights: While the canonical CSL-dependent pathway is the best-understood mode of Notch1 action, studies show that Notch1 has additional non-canonical roles and regulatory modes. For instance, Notch1 and its ligands can interact within the same cell (“cis-interactions”) to inhibit signaling. In a 2024 study, Thambyrajah et al. demonstrated that in embryonic hematopoietic stem cells, Jagged1 ligands expressed on the same cell surface bind Notch1 in cis and prevent its activation, thereby preserving the stem cell fate (pmc.ncbi.nlm.nih.gov). If Notch1 in these cells is forcibly activated (bypassing cis-inhibition), the stem cells prematurely differentiate, indicating that Notch1 inactivity is required to maintain the stem cell state in that context (pmc.ncbi.nlm.nih.gov). This cis-inhibition mechanism highlights how cells can autonomously modulate Notch1 signaling strength by co-expressing ligands, adding a layer of control beyond external ligand availability. Another frontier in Notch1 biology is its transcription-independent functions. A 2023 study reported a form of “Notch1 cortical signaling” in which the Notch1 protein at the cell membrane (particularly the transmembrane domain and remaining juxtamembrane portions after NICD release) helps organize the cortical actin cytoskeleton and cell–cell junctions (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). White et al. (2023) found that Notch1 at epithelial adherens junctions interacts with an effector protein FAM83H and stabilizes E-cadherin-based cell adhesion, which in turn restrains EGFR signaling and excessive cell proliferation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Notably, this structural role required the presence of the Notch1 transmembrane segment (TMD) but not the NICD, suggesting it operates independently of gene transcription. Such non-canonical functions appear specialized (observed in mammary epithelial architectures and previously in endothelial cells (pmc.ncbi.nlm.nih.gov)) but reveal that Notch1 receptors can influence cell architecture and signaling at the cortex in addition to their classical nuclear role. These discoveries underscore that Notch1 is a versatile signaling module, with ongoing research uncovering new modes of action.

Biological Functions in Development and Homeostasis

Developmental roles: Notch1 is a master regulator of cell fate during embryonic development. Through iterative cell–cell signaling events, Notch1 helps pattern tissues and coordinate differentiation. In general, Notch1 activation tends to maintain an undifferentiated state or progenitor character in cells that receive the signal, thereby postponing or redirecting their differentiation. For example, in the nervous system, Notch1 signaling in neural progenitor cells inhibits neuronal differentiation, ensuring that not all cells convert into neurons at once. This mechanism – initially discovered from the neurogenic phenotype of Notch mutants in flies – is conserved in mammals and is critical for balancing neural stem cell maintenance with neuron production (www.nature.com). Loss of Notch activity in neural precursors leads to premature neuronal differentiation and depletion of the progenitor pool, whereas excessive Notch1 can block neurons from forming. Notch1 also plays repeated roles at later stages of neurodevelopment, influencing gliogenesis and synaptic patterning (often through induction of Hes/Hey genes that suppress proneural factors). Because of these roles, Notch1 is required for proper brain development and has been implicated in neurodevelopmental disorders when dysregulated (www.nature.com).

In the hematopoietic and immune system, Notch1 provides a famous example of a binary cell-fate switch. Notch1 signaling is essential for T-cell lineage commitment in the thymus. Experimental studies showed that if Notch1 is disabled in hematopoietic progenitor cells, those progenitors fail to become T cells and instead default to the B-cell lineage – even when they reside in the thymic environment (pmc.ncbi.nlm.nih.gov). In a landmark 2001 study, Radtke and colleagues demonstrated that Notch1–deficient common lymphoid precursors adopt a B cell fate in the thymus, whereas normally the thymus (via Notch-Delta signals) instructs them to become T cells (pmc.ncbi.nlm.nih.gov). Thus, Notch1 serves as a pivotal switch that directs lymphoid precursors towards the T cell program and away from the B cell program. Consistently, Delta-like ligands (especially DLL4) presented by thymic epithelial cells activate Notch1 on immigrant progenitors to trigger the T-cell developmental pathway. Beyond T cells, Notch1 (and related receptors) also influence other blood cell lineages and the formation of hematopoietic stem cells. During embryogenesis, Notch1 is required for the emergence of definitive hematopoietic stem cells from hemogenic endothelium in the aorta-gonad-mesonephros region (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). If Notch signaling is blocked at that stage, fewer HSCs are produced. In the adult bone marrow, Notch signals (from niche cells) continue to support HSC maintenance and may bias differentiation outcomes for lymphocytes and other lineages, although redundancy with other Notch receptors exists.

Notch1 is indispensable for proper organogenesis and tissue patterning. Mice lacking functional Notch1 die in mid-gestation, reflecting widespread developmental failures (www.nature.com). Notch1-null or Notch1 signal–deficient embryos display defects in somite segmentation (leading to irregular formation of the vertebral column segments) and in vascular development (www.nature.com). Notch1, together with DLL1 and DLL4, is crucial for the formation of the embryonic vasculature: it helps specify arterial endothelial cell identity and coordinate angiogenic sprouting. For instance, in developing blood vessels, cells with higher Notch1 activity adopt an arterial fate while suppressing venous differentiation, and Notch1-DLL4 interactions between endothelial tip and stalk cells refine the pattern of new vessel branching. Notch1 is also involved in the development of the heart (cardiac outflow tract and valves), pancreas, kidneys, and many other structures by modulating the differentiation of progenitors in those tissues. In each context, Notch1 often acts reiteratively: for example, controlling the proliferation of a progenitor pool, then later influencing the choice of specific cell subtypes that arise. Many of these roles have been defined by conditional knockout studies in mice. In the intestinal epithelium, Notch1 and Notch2 signals maintain the balance between absorptive enterocytes and secretory cells (goblet and others) – Notch activation promotes the absorptive cell fate and prevents secretory differentiation. Accordingly, inhibiting Notch (with γ-secretase inhibitors) in adult mice causes a rapid increase in goblet cells in the gut and loss of proliferative crypt progenitors, explaining why diarrhea is a side effect of systemic Notch blockade (pmc.ncbi.nlm.nih.gov). Notch1 signaling similarly maintains stem or progenitor states in the skin, inner ear, lung airways, and other renewing tissues, while coordinating proper differentiation timing. As Bray and Bigas (2025) note, Notch signaling often has “iterative roles” during development – first controlling the state of a progenitor, then later the fate of its progeny – and these roles can continue into adulthood in tissue maintenance and repair (www.nature.com). For example, Notch1 activity persists in adult neural stem cell niches (subventricular zone and hippocampus), where it restrains differentiation and promotes stem cell self-renewal, contributing to ongoing neurogenesis in a regulated manner (www.nature.com). In summary, Notch1’s primary biological function is to act as a context-dependent cell fate regulator: by transmitting local cell–cell signals into changes in gene expression, it shapes developmental patterning and ensures the proper balance between progenitors and differentiated cells in many tissues (pmc.ncbi.nlm.nih.gov) (www.nature.com).

Homeostasis and regeneration: Notch1’s influence extends beyond embryonic development into adult tissue homeostasis. Many adult stem cell systems exploit Notch signaling to control differentiation. We have mentioned the intestine and bone marrow as examples; similarly, in the epidermis, Notch1 promotes differentiation of keratinocytes. When Notch1 is active in a basal skin cell, it drives that cell to exit the stem cell compartment and differentiate into a spinous/intermediate cell, helping form the stratified layers. If Notch1 is lost in skin progenitors, those cells can expand excessively and fail to differentiate properly (www.nature.com). This role of Notch1 in inducing differentiation in skin (and thus restraining unchecked growth) is one reason that Notch1 is considered a tumor suppressor in the epidermis – Notch1-deficient skin can develop epidermal cancers (squamous cell carcinomas) due to accumulation of undifferentiated, proliferative cells (www.nature.com). In other contexts, Notch1 can act to support proliferation: for example, Notch signaling is involved in liver regeneration and cardiac injury responses, where it may help reactive progenitor cells expand or transform. The outcome depends on how the Notch1 targets interface with other pathways (e.g. Notch1 crosstalks with Wnt, TGF-β, and hypoxia pathways in various stem cell niches (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov)). Overall, Notch1 provides a means for cells in a community (tissue) to communicate and coordinate behavior, maintaining tissue architecture. This is vividly illustrated by the recent finding that Notch1 at cell junctions strengthens adhesion: in a confluent epithelial layer, Notch1’s presence at the cortex helps cells sense confluency and suppresses further growth (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In summary, from embryogenesis through adulthood, Notch1 plays a “gate-keeper” role in cell fate and differentiation, ensuring the right cells form at the right time and place, and that stem cell pools are neither prematurely exhausted nor overgrown. When this regulation goes awry, developmental defects or diseases can result.

Notch1 in Disease Contexts and Therapeutic Developments

Given its central role in regulating cell proliferation and differentiation, it is not surprising that NOTCH1 is involved in many diseases. Aberrant Notch1 signaling – either excessive or deficient – can contribute to oncogenesis, developmental syndromes, and other pathologies. Notch1 is somewhat unusual in that it can function as an oncogene in some tissues and a tumor suppressor in others (pmc.ncbi.nlm.nih.gov) (www.nature.com).

Oncogenic Notch1: The clearest example of Notch1 as an oncogenic driver is in T-cell acute lymphoblastic leukemia (T-ALL). NOTCH1 was first linked to human T-ALL in the early 1990s, and subsequent genomic studies revealed that more than 50% of T-ALL patients have somatic activating mutations in the NOTCH1 gene (pmc.ncbi.nlm.nih.gov). These mutations typically occur either in the HD domain (extracellular heterodimerization region) or in the C-terminal PEST domain of Notch1 (pmc.ncbi.nlm.nih.gov). HD domain mutations (e.g. small deletions or amino-acid substitutions) destabilize the autoinhibited conformation, essentially making the receptor prone to ligand-independent activation (pmc.ncbi.nlm.nih.gov). PEST domain mutations remove the degron signals, prolonging the NICD’s half-life in the nucleus (pmc.ncbi.nlm.nih.gov). Both types of mutations lead to excessive Notch1 signaling in T-cell progenitors. This drives leukemia by altering transcription of genes that control cell growth and metabolism – for example, Notch1 directly upregulates MYC and other oncogenic programs in T-ALL cells (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In mouse models, forced activation of Notch1 in hematopoietic stem cells or thymocytes is sufficient to induce T-cell leukemias (pmc.ncbi.nlm.nih.gov). The clinical relevance is significant: NOTCH1 status is being explored as a prognostic marker in T-ALL, and components of Notch signaling are targets for therapy (see below). Notch1 is also mutated or overactivated in certain solid tumors. For instance, about 10–15% of human non-small cell lung carcinomas (especially lung adenocarcinoma) have mutations in Notch pathway genes, sometimes including NOTCH1. Notch1 activation is linked to poor differentiation and stem-like tumor cell phenotype in some solid cancers such as triple-negative breast cancer and pancreatic ductal carcinoma (pmc.ncbi.nlm.nih.gov). On the other hand, in some tumors Notch1 acts as a tumor suppressor: frequent loss-of-function mutations in NOTCH1 are found in squamous cell carcinomas of the skin, esophagus, and head and neck (www.nature.com), suggesting that when Notch1’s prodifferentiation signal is removed, cells become prone to malignant transformation. Indeed, a study in mouse skin showed that Notch1 deletion led to spontaneous basal cell carcinomas, whereas activating Notch1 caused those cells to exit the cell cycle via differentiation (www.nature.com). This dichotomy exemplifies the context-dependent nature of Notch1 – promoting cancer in settings like T cells (where it sustains an undifferentiated, proliferative state) but suppressing cancer in settings like stratified epithelia (where it is needed to induce differentiation of potential cancer-initiating cells). Beyond cancer, germline mutations in Notch pathway components can cause developmental disorders. NOTCH1 germline mutations in humans have been associated with congenital heart defects, such as bicuspid aortic valve and left ventricular outflow tract malformations (pmc.ncbi.nlm.nih.gov). In these cases, heterozygous loss of Notch1 impairs valve formation and can lead to early-onset calcification of valves (pmc.ncbi.nlm.nih.gov). (Mutations in the ligand JAG1 or in NOTCH2 cause Alagille syndrome, a complex developmental disease affecting the liver, heart, and other organs (pmc.ncbi.nlm.nih.gov) – highlighting again that balanced Notch signaling is vital for normal organ development.)

Therapeutic targeting of Notch1: The prominent role of Notch1 in diseases like T-ALL has motivated efforts to develop Notch pathway inhibitors. The simplest way to block Notch signaling is to prevent NICD production via γ-secretase inhibitors (GSIs), since γ-secretase is required for S3 cleavage of all Notch receptors. In fact, one of the first clinical trials (launched in 2006) for Notch-related therapy used a GSI (MK-0752) in patients with refractory T-ALL (pmc.ncbi.nlm.nih.gov). The drug did achieve a reduction in leukemia burden in some cases (one T-ALL patient had ~45% tumor mass reduction in 4 weeks), but unfortunately the trial had to be halted due to dose-limiting toxicity – namely, severe gastrointestinal side effects (secretory diarrhea) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This toxicity was anticipated from animal studies: GSIs cause an overproduction of goblet cells in the intestines by blocking Notch1/2, disrupting gut homeostasis. The GSI trial outcome underscored a key challenge: Notch1 is so important in normal physiology that systemic inhibition leads to mechanism-related side effects (pmc.ncbi.nlm.nih.gov). Since then, researchers have pursued more selective strategies to inhibit Notch1 in cancer while sparing other tissues. One approach has been to develop monoclonal antibodies against specific Notch receptors or ligands. Brontictuzumab is a humanized antibody that binds the negative regulatory region of NOTCH1, stabilizing the autoinhibited conformation and preventing ligand activation. In a Phase I study (initiated 2013) of brontictuzumab in patients with advanced solid tumors, there were signs of anti-tumor activity: 2 out of 48 patients achieved partial tumor responses and 4 others had stable disease for ≥6 months, particularly in tumors like adenoid cystic carcinoma that are known to often have aberrant Notch activation (pmc.ncbi.nlm.nih.gov). Notably, adenoid cystic carcinomas with activating NOTCH1 mutations responded, suggesting target engagement (pmc.ncbi.nlm.nih.gov). However, even with this receptor-specific blockade, toxicities were observed – including grade 3 diarrhea and fatigue in some patients, which were dose-limiting (pmc.ncbi.nlm.nih.gov). These events reflect on-target effects of Notch1 inhibition in normal gut and perhaps other tissues. Other Notch-targeting agents have been tested, such as antibodies against Notch2/3 (e.g. tarextumab) and ligand blockers or decoys, with mixed results and sometimes unexpected pro-tumor effects in certain contexts (since Notch can also suppress tumors). There are also inhibitors of the Notch transcription complex under investigation (e.g. small molecules inhibiting RBPJ–NICD interaction or MAML function) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), which might offer another route to dial down Notch1-driven gene expression. None of these therapies have yet achieved regulatory approval, due in part to the narrow therapeutic window.

Interestingly, one area where Notch1 status is being leveraged is cancer immunotherapy. Emerging evidence suggests that tumors harboring Notch pathway mutations (often loss-of-function) may respond differently to immune checkpoint blockade. Notch-inactivating mutations can lead to a less differentiated, more antigenic tumor cell phenotype and a pro-inflammatory microenvironment – for example, via increased T cell infiltration or higher expression of immune genes (pmc.ncbi.nlm.nih.gov). A recent clinical study in 2023 found that NSCLC patients with NOTCH1 mutations had significantly better outcomes on PD-1/PD-L1 inhibitor therapy than those with wild-type Notch1 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Specifically, NOTCH1-mutant lung cancer patients showed higher tumor mutational burden and achieved superior overall survival under checkpoint blockade (median overall survival was longer, and on multivariate analysis Notch1 mutation was associated with a hazard ratio ~0.4 for death) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This suggests that loss of Notch1 signaling in a tumor might increase immune visibility (perhaps by upregulating neoantigen expression or interferon pathways), making them more susceptible to immunotherapy. While this finding needs further validation, it points to NOTCH1 mutation as a potential biomarker for immunotherapy response in certain cancers. More broadly, it exemplifies how deepening our understanding of Notch1’s role in tumor biology could inform personalized treatment strategies – either by directly targeting the pathway or by exploiting its downstream effects on tumor–immune interactions.

Conclusion: Notch1 is a fundamental signaling protein that ties together cell-to-cell communication with gene regulation. Through its ligand-induced proteolysis mechanism, Notch1 directly converts external signals at the cell membrane into changes in transcriptional programs in the nucleus. It controls critical decisions in cell fate, proliferation, and differentiation in a context-dependent manner. Modern research (2023–2024) continues to reveal new facets of Notch1 biology – from cis-inhibitory loops that fine-tune stem cell signals (pmc.ncbi.nlm.nih.gov), to non-traditional roles in strengthening cell junctions and controlling cell polarity (pmc.ncbi.nlm.nih.gov). These insights expand our view of how Notch1 functions beyond the classical paradigm. Clinically, Notch1 stands as a double-edged sword: its dysregulation can lead to severe diseases, yet it is a challenging therapeutic target due to its importance in normal physiology. Ongoing work in developmental biology, structural biochemistry, and clinical oncology is converging to unravel how to modulate Notch1 safely and effectively. By learning how Notch1’s “molecular decisions” are made and modulated, scientists hope to design interventions that can, for example, shut down a Notch1-driven leukemia or stimulate regenerative healing in tissues, without collateral damage. Notch1 thus remains a focus of intense research as both a paradigm of cell signaling and a key node in human health and disease (pmc.ncbi.nlm.nih.gov) (www.nature.com).

References: (Publication dates and URLs are provided in citations throughout the text)

Citations

  1. AnnotationURLCitation(end_index=519, start_index=379, title='Embryonic lethality in mice homozygous for a processing-deficient allele of Notch1 | Nature', type='url_citation', url='https://www.nature.com/articles/35016111#:~:text=The%20Notch%20genes%20encode%20single,11%7D.%20Not%20all%20observations')
  2. AnnotationURLCitation(end_index=679, start_index=520, title='Modes of Notch signalling in development and disease | Nature Reviews Molecular Cell Biology', type='url_citation', url='https://www.nature.com/articles/s41580-025-00835-2#:~:text=Many%20different%20animal%20developmental%20and,that%20it%20has%20many%20diverse')
  3. AnnotationURLCitation(end_index=1073, start_index=914, title='Modes of Notch signalling in development and disease | Nature Reviews Molecular Cell Biology', type='url_citation', url='https://www.nature.com/articles/s41580-025-00835-2#:~:text=Many%20different%20animal%20developmental%20and,that%20it%20has%20many%20diverse')
  4. AnnotationURLCitation(end_index=1613, start_index=1454, title='Modes of Notch signalling in development and disease | Nature Reviews Molecular Cell Biology', type='url_citation', url='https://www.nature.com/articles/s41580-025-00835-2#:~:text=Many%20different%20animal%20developmental%20and,that%20it%20has%20many%20diverse')
  5. AnnotationURLCitation(end_index=1941, start_index=1786, title='Modes of Notch signalling in development and disease | Nature Reviews Molecular Cell Biology', type='url_citation', url='https://www.nature.com/articles/s41580-025-00835-2#:~:text=state%20of%20progenitor%20cells%20but,was%20uncovered%2C%20and%20it%20became')
  6. AnnotationURLCitation(end_index=2457, start_index=2300, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=The%20extracellular%20domain%20%28N,domain%20are%20involved%20in%20ligand')
  7. AnnotationURLCitation(end_index=2774, start_index=2617, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=The%20extracellular%20domain%20%28N,domain%20are%20involved%20in%20ligand')
  8. AnnotationURLCitation(end_index=3070, start_index=2946, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=binding,for%20the%20stability%20of%20the')
  9. AnnotationURLCitation(end_index=3516, start_index=3359, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=apparatus%2C%20NOTCH%20receptors%20are%20cleaved,secretase.%20The%20NOTCH')
  10. AnnotationURLCitation(end_index=3650, start_index=3517, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=then%20experience%20S3%20cleavage%2C%20changing,2')
  11. AnnotationURLCitation(end_index=3913, start_index=3756, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=apparatus%2C%20NOTCH%20receptors%20are%20cleaved,secretase.%20The%20NOTCH')
  12. AnnotationURLCitation(end_index=4196, start_index=4036, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=NOTCH%20receptors%20are%20resistant%20to,NEXT%20can%20be%20further%20cleaved')
  13. AnnotationURLCitation(end_index=4334, start_index=4197, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=S2%20cleavage%20is%20the%20only,58%7D.%20Once%20bound')
  14. AnnotationURLCitation(end_index=4788, start_index=4628, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=NOTCH%20receptors%20are%20resistant%20to,NEXT%20can%20be%20further%20cleaved')
  15. AnnotationURLCitation(end_index=5061, start_index=4901, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=NOTCH%20receptors%20are%20resistant%20to,NEXT%20can%20be%20further%20cleaved')
  16. AnnotationURLCitation(end_index=5442, start_index=5309, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=then%20experience%20S3%20cleavage%2C%20changing,2')
  17. AnnotationURLCitation(end_index=5726, start_index=5593, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=then%20experience%20S3%20cleavage%2C%20changing,2')
  18. AnnotationURLCitation(end_index=5991, start_index=5858, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=then%20experience%20S3%20cleavage%2C%20changing,2')
  19. AnnotationURLCitation(end_index=6521, start_index=6365, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=Located%20after%20the%20membrane,like%20repeats%2C%20the%20glycosylation')
  20. AnnotationURLCitation(end_index=6852, start_index=6678, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=the%20nucleus%2C%20and%20seven%20ankyrin,is%20controlled%20by%20constitutive%20endocytosis')
  21. AnnotationURLCitation(end_index=6981, start_index=6853, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=domains,4%20have%20similar%20structures%20to')
  22. AnnotationURLCitation(end_index=7354, start_index=7181, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=contain%20degradation%20signals%20and%20are,appreciable%20amount%20of%20NOTCH%20receptors')
  23. AnnotationURLCitation(end_index=7827, start_index=7680, title='Embryonic lethality in mice homozygous for a processing-deficient allele of Notch1 | Nature', type='url_citation', url='https://www.nature.com/articles/35016111#:~:text=emerge%20for%20the%20Notch%20signalling,associated%20with%20a%20single%20point')
  24. AnnotationURLCitation(end_index=7992, start_index=7828, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=match%20at%20L1990%20which%20contains,inhibitor%20of%20MAML1%2C%20inhibits%20the')
  25. AnnotationURLCitation(end_index=8313, start_index=8155, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=In%20the%20traditional%20model%20of,targeting%20MAML%20are%20under%20study')
  26. AnnotationURLCitation(end_index=8628, start_index=8470, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=In%20the%20traditional%20model%20of,targeting%20MAML%20are%20under%20study')
  27. AnnotationURLCitation(end_index=8793, start_index=8629, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=match%20at%20L1990%20which%20contains,inhibitor%20of%20MAML1%2C%20inhibits%20the')
  28. AnnotationURLCitation(end_index=9179, start_index=9021, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=In%20the%20traditional%20model%20of,targeting%20MAML%20are%20under%20study')
  29. AnnotationURLCitation(end_index=9425, start_index=9261, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=match%20at%20L1990%20which%20contains,inhibitor%20of%20MAML1%2C%20inhibits%20the')
  30. AnnotationURLCitation(end_index=9584, start_index=9426, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=In%20the%20traditional%20model%20of,targeting%20MAML%20are%20under%20study')
  31. AnnotationURLCitation(end_index=9895, start_index=9806, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=co,23')
  32. AnnotationURLCitation(end_index=10573, start_index=10433, title='Embryonic lethality in mice homozygous for a processing-deficient allele of Notch1 | Nature', type='url_citation', url='https://www.nature.com/articles/35016111#:~:text=The%20Notch%20genes%20encode%20single,11%7D.%20Not%20all%20observations')
  33. AnnotationURLCitation(end_index=10926, start_index=10776, title='Notch signaling pathway: architecture, disease, and therapeutics - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/35332121/#:~:text=the%20transcription%20of%20target%20genes,Collectively%2C%20the%20NOTCH')
  34. AnnotationURLCitation(end_index=11099, start_index=10927, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=development%20and%20homeostasis%20of%20multiple,with%20new%20perspectives%20to%20inspire')
  35. AnnotationURLCitation(end_index=11338, start_index=11234, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=three%20cleavages,42')
  36. AnnotationURLCitation(end_index=11616, start_index=11496, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=Humans%20and%20mice%20have%20five,50')
  37. AnnotationURLCitation(end_index=12186, start_index=12031, title='Notch 1–Deficient Common Lymphoid Precursors Adopt a B Cell Fate in the Thymus - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2193487/#:~:text=Notch%20proteins%20have%20been%20shown,family%20members%20in%20T%20cell')
  38. AnnotationURLCitation(end_index=12984, start_index=12847, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=domains,appreciable%20amount%20of%20NOTCH%20receptors')
  39. AnnotationURLCitation(end_index=13431, start_index=13271, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=of%20NOTCH%20receptors%20is%20involved,loss%20of%20which%20decreases%20NOTCH')
  40. AnnotationURLCitation(end_index=14112, start_index=13975, title='Cis inhibition of NOTCH1 through JAGGED1 sustains embryonic hematopoietic stem cell fate - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10882055/#:~:text=inconsistent,clusters%20of%20the%20embryonic%20aorta')
  41. AnnotationURLCitation(end_index=14492, start_index=14329, title='Cis inhibition of NOTCH1 through JAGGED1 sustains embryonic hematopoietic stem cell fate - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10882055/#:~:text=uncover%20that%20the%20HSC%20phenotype,clusters%20of%20the%20embryonic%20aorta')
  42. AnnotationURLCitation(end_index=15227, start_index=15045, title='Notch1 cortical signaling regulates epithelial architecture and cell–cell adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10555887/#:~:text=Notch1%20cortical%20signaling%20mechanism%20that,control%20of%20epithelial%20adherens%20junctions')
  43. AnnotationURLCitation(end_index=15379, start_index=15228, title='Notch1 cortical signaling regulates epithelial architecture and cell–cell adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10555887/#:~:text=These%20findings%20are%20consistent%20with,ICD%20or%20a%20TMD%20in')
  44. AnnotationURLCitation(end_index=15769, start_index=15615, title='Notch1 cortical signaling regulates epithelial architecture and cell–cell adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10555887/#:~:text=transcriptional%20signaling,actin%20through%20the%20effector%20FAM83H')
  45. AnnotationURLCitation(end_index=15948, start_index=15770, title='Notch1 cortical signaling regulates epithelial architecture and cell–cell adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10555887/#:~:text=activity%20may%20be%20negatively%20regulated,EGFR%20phosphorylation%2C%20we%20next%20examined')
  46. AnnotationURLCitation(end_index=16431, start_index=16254, title='Notch1 cortical signaling regulates epithelial architecture and cell–cell adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10555887/#:~:text=as%20Notch1%20cortical%20signaling%2C%20where,case%2C%20and%20substantial%20structural%20and')
  47. AnnotationURLCitation(end_index=17696, start_index=17537, title='Modes of Notch signalling in development and disease | Nature Reviews Molecular Cell Biology', type='url_citation', url='https://www.nature.com/articles/s41580-025-00835-2#:~:text=Many%20different%20animal%20developmental%20and,that%20it%20has%20many%20diverse')
  48. AnnotationURLCitation(end_index=18376, start_index=18221, title='Modes of Notch signalling in development and disease | Nature Reviews Molecular Cell Biology', type='url_citation', url='https://www.nature.com/articles/s41580-025-00835-2#:~:text=state%20of%20progenitor%20cells%20but,was%20uncovered%2C%20and%20it%20became')
  49. AnnotationURLCitation(end_index=18954, start_index=18787, title='Notch 1–Deficient Common Lymphoid Precursors Adopt a B Cell Fate in the Thymus - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2193487/#:~:text=a%20bipotential%20T%2FB%20precursor%20toward,of%20lymphoid%20precursors%20to%20home')
  50. AnnotationURLCitation(end_index=19359, start_index=19192, title='Notch 1–Deficient Common Lymphoid Precursors Adopt a B Cell Fate in the Thymus - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2193487/#:~:text=a%20bipotential%20T%2FB%20precursor%20toward,of%20lymphoid%20precursors%20to%20home')
  51. AnnotationURLCitation(end_index=20122, start_index=19967, title='Cis inhibition of NOTCH1 through JAGGED1 sustains embryonic hematopoietic stem cell fate - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10882055/#:~:text=Hematopoietic%20stem%20cells%20,to%20increasing%20levels%20of%20NOTCH1')
  52. AnnotationURLCitation(end_index=20294, start_index=20123, title='Cis inhibition of NOTCH1 through JAGGED1 sustains embryonic hematopoietic stem cell fate - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10882055/#:~:text=signaling%20is%20essential%20for%20arterial,HSC%20phenotype%20in%20the%20hematopoietic')
  53. AnnotationURLCitation(end_index=20927, start_index=20766, title='Embryonic lethality in mice homozygous for a processing-deficient allele of Notch1 | Nature', type='url_citation', url='https://www.nature.com/articles/35016111#:~:text=clearly%20support%20this%20processing%20model%2C,early%20embryonic%20development%20in%20vivo')
  54. AnnotationURLCitation(end_index=21278, start_index=21117, title='Embryonic lethality in mice homozygous for a processing-deficient allele of Notch1 | Nature', type='url_citation', url='https://www.nature.com/articles/35016111#:~:text=clearly%20support%20this%20processing%20model%2C,early%20embryonic%20development%20in%20vivo')
  55. AnnotationURLCitation(end_index=22821, start_index=22673, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=patients%20with%20T,in%20preclinical%20and%20clinical%20settings')
  56. AnnotationURLCitation(end_index=23420, start_index=23261, title='Modes of Notch signalling in development and disease | Nature Reviews Molecular Cell Biology', type='url_citation', url='https://www.nature.com/articles/s41580-025-00835-2#:~:text=Many%20different%20animal%20developmental%20and,that%20it%20has%20many%20diverse')
  57. AnnotationURLCitation(end_index=23813, start_index=23663, title='Modes of Notch signalling in development and disease | Nature Reviews Molecular Cell Biology', type='url_citation', url='https://www.nature.com/articles/s41580-025-00835-2#:~:text=via%20the%20highly%20conserved%20Notch,that%20it%20has%20many%20diverse')
  58. AnnotationURLCitation(end_index=24270, start_index=24118, title='Notch 1–Deficient Common Lymphoid Precursors Adopt a B Cell Fate in the Thymus - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2193487/#:~:text=match%20at%20L84%20Notch%20proteins,family%20members%20in%20T%20cell')
  59. AnnotationURLCitation(end_index=24426, start_index=24271, title='Modes of Notch signalling in development and disease | Nature Reviews Molecular Cell Biology', type='url_citation', url='https://www.nature.com/articles/s41580-025-00835-2#:~:text=state%20of%20progenitor%20cells%20but,was%20uncovered%2C%20and%20it%20became')
  60. AnnotationURLCitation(end_index=25207, start_index=25071, title='Modes of Notch signalling in development and disease | Nature Reviews Molecular Cell Biology', type='url_citation', url='https://www.nature.com/articles/s41580-025-00835-2#:~:text=match%20at%20L586%20136,33%2C%20416%E2%80%93421%20%282003')
  61. AnnotationURLCitation(end_index=25663, start_index=25527, title='Modes of Notch signalling in development and disease | Nature Reviews Molecular Cell Biology', type='url_citation', url='https://www.nature.com/articles/s41580-025-00835-2#:~:text=match%20at%20L586%20136,33%2C%20416%E2%80%93421%20%282003')
  62. AnnotationURLCitation(end_index=26221, start_index=26057, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=cleavage%20and%20thus%20NOTCH%20signaling,to%20amplify%20the%20immune%20response')
  63. AnnotationURLCitation(end_index=26391, start_index=26222, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=Independent%20of%20CSL%2C%20NICD%20can,%CE%BAB%2C%20mTORC%2C%20PTEN%2C%20AKT%2C%20Wnt')
  64. AnnotationURLCitation(end_index=26938, start_index=26760, title='Notch1 cortical signaling regulates epithelial architecture and cell–cell adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10555887/#:~:text=activity%20may%20be%20negatively%20regulated,EGFR%20phosphorylation%2C%20we%20next%20examined')
  65. AnnotationURLCitation(end_index=27090, start_index=26939, title='Notch1 cortical signaling regulates epithelial architecture and cell–cell adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10555887/#:~:text=These%20findings%20are%20consistent%20with,ICD%20or%20a%20TMD%20in')
  66. AnnotationURLCitation(end_index=28029, start_index=27888, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=match%20at%20L1039%20T,NOTCH1%20has%20also%20been%20found')
  67. AnnotationURLCitation(end_index=28119, start_index=28030, title='Modes of Notch signalling in development and disease | Nature Reviews Molecular Cell Biology', type='url_citation', url='https://www.nature.com/articles/s41580-025-00835-2#:~:text=135,Cancer')
  68. AnnotationURLCitation(end_index=28588, start_index=28447, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=match%20at%20L1039%20T,NOTCH1%20has%20also%20been%20found')
  69. AnnotationURLCitation(end_index=28862, start_index=28731, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=T,Furthermore%2C%20mutations%20disrupting%20the')
  70. AnnotationURLCitation(end_index=29185, start_index=29054, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=T,Furthermore%2C%20mutations%20disrupting%20the')
  71. AnnotationURLCitation(end_index=29418, start_index=29287, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=T,Furthermore%2C%20mutations%20disrupting%20the')
  72. AnnotationURLCitation(end_index=29811, start_index=29691, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=T,NOTCH1%20has%20also%20been%20found')
  73. AnnotationURLCitation(end_index=29958, start_index=29812, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=match%20at%20L1131%20N,as%20LUNAR1%2C%20which%20is%20essential')
  74. AnnotationURLCitation(end_index=30208, start_index=30088, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=T,NOTCH1%20has%20also%20been%20found')
  75. AnnotationURLCitation(end_index=30964, start_index=30802, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=NOTCH%20was%20first%20identified%20as,cancer%20and%20colorectal%20cancer%20was')
  76. AnnotationURLCitation(end_index=31307, start_index=31171, title='Modes of Notch signalling in development and disease | Nature Reviews Molecular Cell Biology', type='url_citation', url='https://www.nature.com/articles/s41580-025-00835-2#:~:text=match%20at%20L586%20136,33%2C%20416%E2%80%93421%20%282003')
  77. AnnotationURLCitation(end_index=31749, start_index=31613, title='Modes of Notch signalling in development and disease | Nature Reviews Molecular Cell Biology', type='url_citation', url='https://www.nature.com/articles/s41580-025-00835-2#:~:text=match%20at%20L586%20136,33%2C%20416%E2%80%93421%20%282003')
  78. AnnotationURLCitation(end_index=32443, start_index=32338, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=Adams,645%E2%80%93647')
  79. AnnotationURLCitation(end_index=32670, start_index=32565, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=Adams,645%E2%80%93647')
  80. AnnotationURLCitation(end_index=32969, start_index=32821, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=leukemia%20%28T,these%20discoveries%2C%20the%20relationship%20of')
  81. AnnotationURLCitation(end_index=33678, start_index=33530, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=patients%20with%20T,in%20preclinical%20and%20clinical%20settings')
  82. AnnotationURLCitation(end_index=34103, start_index=33955, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=patients%20with%20T,in%20preclinical%20and%20clinical%20settings')
  83. AnnotationURLCitation(end_index=34237, start_index=34104, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=match%20at%20L1799%20treatment%20in,Other%20drugs')
  84. AnnotationURLCitation(end_index=34715, start_index=34567, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=patients%20with%20T,in%20preclinical%20and%20clinical%20settings')
  85. AnnotationURLCitation(end_index=35630, start_index=35462, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=NOTCH1%20%20%7C%20Brontictuzumab%20%28OMP,DLTs%20included%20diarrhea%20and%20fatigue')
  86. AnnotationURLCitation(end_index=35908, start_index=35740, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=NOTCH1%20%20%7C%20Brontictuzumab%20%28OMP,DLTs%20included%20diarrhea%20and%20fatigue')
  87. AnnotationURLCitation(end_index=36213, start_index=36075, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=NCT01778439,DLTs%20included%20diarrhea%20and%20fatigue')
  88. AnnotationURLCitation(end_index=36892, start_index=36728, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=match%20at%20L1990%20which%20contains,inhibitor%20of%20MAML1%2C%20inhibits%20the')
  89. AnnotationURLCitation(end_index=37051, start_index=36893, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=In%20the%20traditional%20model%20of,targeting%20MAML%20are%20under%20study')
  90. AnnotationURLCitation(end_index=37842, start_index=37711, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=T,response%2C%20PR%20partial%20response%2C%20SD')
  91. AnnotationURLCitation(end_index=38155, start_index=38027, title='NOTCH1 Mutations Predict Superior Outcomes of Immune Checkpoint Blockade in Non-Small Cell Lung Cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10710100/#:~:text=NOTCH1%20is%20frequently%20mutated%20in,ICB')
  92. AnnotationURLCitation(end_index=38285, start_index=38156, title='NOTCH1 Mutations Predict Superior Outcomes of Immune Checkpoint Blockade in Non-Small Cell Lung Cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10710100/#:~:text=significantly%20superior%20OS%20than%20WT,WT')
  93. AnnotationURLCitation(end_index=38700, start_index=38572, title='NOTCH1 Mutations Predict Superior Outcomes of Immune Checkpoint Blockade in Non-Small Cell Lung Cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10710100/#:~:text=NOTCH1%20is%20frequently%20mutated%20in,ICB')
  94. AnnotationURLCitation(end_index=38830, start_index=38701, title='NOTCH1 Mutations Predict Superior Outcomes of Immune Checkpoint Blockade in Non-Small Cell Lung Cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10710100/#:~:text=significantly%20superior%20OS%20than%20WT,WT')
  95. AnnotationURLCitation(end_index=40127, start_index=39990, title='Cis inhibition of NOTCH1 through JAGGED1 sustains embryonic hematopoietic stem cell fate - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10882055/#:~:text=inconsistent,clusters%20of%20the%20embryonic%20aorta')
  96. AnnotationURLCitation(end_index=40367, start_index=40216, title='Notch1 cortical signaling regulates epithelial architecture and cell–cell adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10555887/#:~:text=These%20findings%20are%20consistent%20with,ICD%20or%20a%20TMD%20in')
  97. AnnotationURLCitation(end_index=41334, start_index=41176, title='Notch signaling pathway: architecture, disease, and therapeutics - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8948217/#:~:text=In%20the%20traditional%20model%20of,targeting%20MAML%20are%20under%20study')
  98. AnnotationURLCitation(end_index=41490, start_index=41335, title='Modes of Notch signalling in development and disease | Nature Reviews Molecular Cell Biology', type='url_citation', url='https://www.nature.com/articles/s41580-025-00835-2#:~:text=state%20of%20progenitor%20cells%20but,was%20uncovered%2C%20and%20it%20became')